Literature DB >> 7996298

Anticoagulation therapy and primary care internal medicine: a nurse practitioner model for combined clinical science.

D M Becker1, L K DeMong, P Kaplan, R Hutchinson, C M Callahan, S D Fihn, R H White.   

Abstract

The anticoagulation clinics at the University of Virginia Health Sciences Center and the University of California at Davis Medical Center are nurse-practitioner-operated, are affiliated with the general medicine clinic, and rely on portable prothrombin time (PT) monitors that use whole blood and provide timely as well as accurate results reported in PT seconds or as the international normalized ratio (INR). On-site PT/INR testing at these clinics simplifies anticoagulation, mandates direct patient contact, and facilitates primary as well as comprehensive care for patients requiring multispecialty services in large tertiary care centers. Encounters are relatively brief, averaging 19 minutes; 72% of the encounter time involves anticoagulation care and 28% involves primary care. Anticoagulation results using portable PT/INR monitors are safe and accurate based on comparisons with results from clinics relying on standard instruments.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7996298     DOI: 10.1007/BF02599227

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  11 in total

1.  Substandard monitoring of warfarin in North America. Time for change.

Authors:  J Hirsh
Journal:  Arch Intern Med       Date:  1992-02

2.  The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic.

Authors:  H I Bussey; R M Rospond; C M Quandt; G M Clark
Journal:  Pharmacotherapy       Date:  1989       Impact factor: 4.705

3.  Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal hospital setting.

Authors:  F B Davis; M T Estruch; E B Samson-Corvera; G C Voigt; J D Tobin
Journal:  Arch Intern Med       Date:  1977-02

4.  Evaluation of a pharmacist-managed anticoagulation clinic.

Authors:  I A Cohen; T A Hutchison; D M Kirking; M E Shue
Journal:  J Clin Hosp Pharm       Date:  1985-06

5.  Management of oral anticoagulant therapy. Experience with an anticoagulation clinic.

Authors:  A M Errichetti; A Holden; J Ansell
Journal:  Arch Intern Med       Date:  1984-10

6.  Accuracy and precision of a portable anticoagulation monitor in a clinical setting.

Authors:  S A McCurdy; R H White
Journal:  Arch Intern Med       Date:  1992-03

7.  A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. National Consortium of Anticoagulation Clinics.

Authors:  S D Fihn; M B McDonell; D Vermes; J G Henikoff; D C Martin; C M Callahan; D L Kent; R H White
Journal:  J Gen Intern Med       Date:  1994-03       Impact factor: 5.128

8.  Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group.

Authors:  S D Fihn; M McDonell; D Martin; J Henikoff; D Vermes; D Kent; R H White
Journal:  Ann Intern Med       Date:  1993-04-01       Impact factor: 25.391

9.  Cost-justification of a clinical pharmacist-managed anticoagulation clinic.

Authors:  D R Gray; S M Garabedian-Ruffalo; S D Chretien
Journal:  Drug Intell Clin Pharm       Date:  1985 Jul-Aug

10.  Standardizing the prothrombin time. Calibrating coagulation instruments as well as thromboplastin.

Authors:  D M Becker; J E Humphries; F B Walker; L K DeMong; J S Bopp; M N Acker
Journal:  Arch Pathol Lab Med       Date:  1993-06       Impact factor: 5.534

View more
  2 in total

1.  US men discussing prostate-specific antigen tests with a physician.

Authors:  Stephanie L McFall
Journal:  Ann Fam Med       Date:  2006 Sep-Oct       Impact factor: 5.166

2.  Emergency nurse practitioners: a three part study in clinical and cost effectiveness.

Authors:  M Sakr; R Kendall; J Angus; A Sanders; J Nicholl; J Wardrope; A Saunders
Journal:  Emerg Med J       Date:  2003-03       Impact factor: 2.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.